R-Loop Export Drives Inflammaging — and Blocking It Extends Healthspan
Scientists identify a novel molecular pathway linking nuclear R-loops to chronic age-related inflammation, with a druggable target already in clinical use.
Summary
Researchers at MD Anderson and the Wistar Institute discovered that aging cells export unusual nucleic acid structures called R-loops from the nucleus into the cytoplasm. Once outside, these R-loops trigger the cell's innate immune alarm system, fueling the toxic inflammatory secretions that drive age-related disease. A protein complex involving DDX1 and XPO1 acts as the export machinery. Blocking XPO1 with KPT-330, a drug already approved for certain cancers, reduced this R-loop export, dampened inflammatory signaling, and extended healthspan in experimental models. This work reveals a previously unknown mechanism connecting cellular senescence to inflammaging and points to a concrete intervention target that could be repurposed to combat age-related chronic inflammation.
Detailed Summary
Chronic low-grade inflammation — inflammaging — is one of the most powerful drivers of age-related disease, from cardiovascular decline to neurodegeneration. A key contributor is the senescence-associated secretory phenotype (SASP), through which aging cells flood their surroundings with pro-inflammatory signals. Understanding exactly how senescent cells generate the SASP is essential for developing therapies that could suppress harmful inflammaging without broadly suppressing immunity.
This study, published in Nature Aging, investigates R-loops — three-stranded nucleic acid structures formed when RNA hybridizes to template DNA, displacing the opposite strand. While R-loops are known to influence genome stability and innate immunity in cancer, their role in cellular senescence and aging had been unexplored. The researchers discovered that senescent cells accumulate nuclear-derived R-loops in their cytoplasm, with a notable enrichment in alpha-satellite repeat sequences.
Once exported from the nucleus, these cytoplasmic R-loops localize into cytoplasmic chromatin fragments (CCFs), which activate the cGAS-STING innate immune pathway — a well-established driver of SASP. The export machinery responsible was identified as a complex between XPO1 (exportin-1) and DDX1 (DEAD-Box helicase 1), providing a specific, actionable molecular target.
Critically, inhibiting XPO1 with KPT-330 (selinexor), an FDA-approved cancer drug, blocked R-loop nuclear export, reduced CCF formation, attenuated SASP, mitigated age-associated inflammation, and extended healthspan in experimental models. This drug repurposing angle is particularly compelling given selinexor's existing clinical safety profile.
Caveats include that this summary is based solely on the abstract; full mechanistic details, model organisms used, and effect sizes are unavailable. It also remains unclear how these findings translate to humans and whether XPO1 inhibition at doses safe for aging contexts would be feasible long-term.
Key Findings
- Senescent cells export R-loops from the nucleus into the cytoplasm, enriched in alpha-satellite repeats.
- Cytoplasmic R-loops localize to chromatin fragments that activate cGAS-STING, driving SASP.
- The DDX1-XPO1 protein complex is the essential export machinery for nuclear R-loops.
- XPO1 inhibitor KPT-330 (selinexor) blocks R-loop export, reduces SASP, and extends healthspan in models.
- R-loop nuclear export is proposed as a new druggable target to suppress inflammaging.
Methodology
The study used cellular senescence models to detect and characterize cytoplasmic R-loop accumulation, including localization studies to CCFs and pathway analysis of cGAS-STING activation. XPO1-DDX1 complex involvement was identified through molecular interaction studies. In vivo experiments with KPT-330 assessed effects on inflammation and healthspan, though full methodological details require access to the complete paper.
Study Limitations
This summary is based on the abstract only and does not reflect the full methodology, statistical results, or supplementary data. The specific model organisms and whether healthspan extension translates to humans are unknown. Long-term safety and feasibility of XPO1 inhibition for aging indications versus oncology dosing require dedicated investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.